Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 8/20 | 0.54 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL23629840 | 0.86 | QRFPR (0.57) | QRFPRC3AR1GNPATPTGER4 | |
| SCHEMBL24191552 | 0.86 | F2 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4F2 | |
| SCHEMBL24191596 | 0.85 | CTSK (0.50) | QRFPRC3AR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24191702 | 0.82 | LTA4H (0.52) | — | |
| SCHEMBL29590419 | 0.82 | QRFPR (0.60) | QRFPRGNPAT | |
| SCHEMBL29405927 | 0.82 | LNPEP (0.52) | C3AR1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL29405428 | 0.80 | LNPEP (0.55) | C3AR1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL7471967 | 0.80 | C3AR1 (0.62) | C3AR1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL7442230 | 0.80 | C3AR1 (0.62) | C3AR1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3961412 | 0.79 | QRFPR (0.46) | QRFPRC3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | QRFPR 900/4885C3AR1 143/4885CHRNB2 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.